This site is intended for healthcare professionals
News

Phase II DESTINY-CRC01 trial of Enhertu/Enhurtu demonstrated meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer.- Daiichi Sankyo + AstraZeneca

Read time: 1 mins
Last updated:2nd Jun 2020
Published:2nd Jun 2020
Condition: Colorectal Cancer
Type: drug
Register free for full access to medthority.com